Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Panels 1- 8 and Panels 14-15: healthy male subjects between the ages of 18 to 45

• Panels 9 and 10: healthy elderly males and females ages 60 and greater

• Panel 11: healthy males between the ages of 46-59

• Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI) between the ages of 60 and 74

• Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that were 75 years of age or greater

• Acceptable medical history, physical examinations, vital signs, electrocardiograms, hemoccult stool tests, and clinical laboratory evaluations